Stock AnalizImmunityBio, Inc. IBRX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2015 · data as of November 13, 2026
ImmunityBio, Inc. (IBRX) is a healthcare company listed in the US with a market value of about $6.4B. In the twelve months to September 30, 2026 it had revenue of $183M and net income of -$1.1B, a net margin of -607.8%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 185% a year, a 5-year average ROIC of -789%.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $183M | $113M | $15M | $622000 | $240000 | $934000 | $605000 | $2M | $47000 | $45000 | $44000 |
| Net income | -$1.1B | -$351M | -$414M | -$583M | -$417M | -$347M | -$222M | -$158M | -$96M | -$96M | -$121M |
| Free cash flow | -$297M | -$309M | -$398M | -$397M | -$416M | -$308M | -$173M | -$156M | -$76M | -$84M | -$45M |
| EPS (diluted) | $-1.08 | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 | $-0.59 | $-0.43 | $-1.22 | $-1.20 | $-1.47 |
| Net margin | -607.8% | -310.2% | -2804.8% | -93761.4% | -173600.0% | -37129.6% | -36669.6% | -7165.2% | -204700.0% | -214300.0% | -274600.0% |
| ROIC | — | — | — | — | -789.0% | — | — | -115.9% | -67.0% | -45.1% | -42.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $14.25, 137% above the current price; targets range from $12.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-0.93 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does ImmunityBio pay a dividend?
Not currently.
Is ImmunityBio a good stock to buy?
We do not give buy or sell advice. ImmunityBio scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.